IMST integrates Radiation Performance for LoRa Certification with Keysight
About one year ago, IMST was selected as an accredited LoRa™ Alliance certification test house for LoRaWAN™ certification. “The Certification testing against LoRaWAN V1.0.1 is a success story with more and more end-devices becoming available that have been certified”, said Derek Hunt, Chairman of the LoRa Alliance Certification Committee. However the possibility of connecting an end-device to an operator’s network successfully also depends on the quality of the radio implementation of the end-device.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160919005974/en/
LoRa certification measuring chamber (Photo: Business Wire)
“Operators should impose minimum end-device radio performance criteria to be able to ensure consistent service to all end-users. A way to achieve this is to add radiation performance measurements to the product test cycle”, says Markus Ridder, Head of the Test Department at IMST.
The test setup for the radiation performance was developed and tested in close cooperation with Keysight Technologies.
From a regulatory point of view the main requirement for 868 MHz ISM devices is that the device’s ERP should not radiate in excess of +14 dBm (or 25 mW) for any orientation. This sets the upper bound on the end-device radiated power and also includes the duty cycle restrictions. In general, with the measured effective TRP (Total Radiated Power) the first quality characteristic of an end device can be derived.
“The operator needs to ensure that the end device actually radiates as much power as possible to maximize the robustness and usable data rate of the uplink”, says Mats Hansen from DIGIMONDO, who operate the first public LoRaWAN network in Germany. “In addition a measurement of the device’s receiver performance is required”, states Hansen. This is derived from the fact that LoRaWAN networks are symmetrical, bi-directional networks implying that the receiver performance of the end-device is also important.
For this the TIS (Total Isotropic Sensitivity) is measured, allowing for bi-directional performance characterisation of the end device.
Both measurements are performed in the accredited radio metrology laboratory at IMST. The software required on the end-devices is already installed on the end device if it has already passed the LoRaWAN Certification, which can also be performed in IMST laboratories.
The report that IMST provides as the output from LoRaWAN Radiation Performance measurement gives antenna diagrams showing the minimum and maximum values for the TRP and TIS. Based on these figures, a network operator can grade devices and ensure a good and smooth network availability and performance. Within development these measurements would help manufacturer to improve their designs.
Ruud Schellekens, CEO of 1M2M said:”We like to base our development on facts. IMST’s LoRa measurement reports give us just that!”
Are you interested in our certification services for your LoRa wireless solutions?
If so, contact us at firstname.lastname@example.org.
IMST GmbH is a leading design house and development centre for wireless modules, communication systems, chip design, antennas, EDA software and regulatory certification which uses an in-house certified regulatory test centre. IMST offers a standard product portfolio of radio modules with hardware/software as well as complete system and product design services. Individualised support during every phase of product development including wireless technologies, from initial consulting to series production, is one of the unique selling propositions of IMST. For more information, visit http://www.imst.com
About Keysight Technologies
Keysight is an US company that manufactures test and measurement equipment and software. In 2014, Keysight was spun off from Agilent Technologies, bringing with it the product lines focused on electronics and radio, leaving Agilent with the chemical and bio-analytical products.
About LoRa™ Alliance
The LoRa™ Alliance is an open, non-profit association has grown to over 370 members since its inception in March 2015, becoming one of the largest and fastest growing alliances in the technology sector. Its members are closely collaborating and sharing their experience to promote the LoRaWAN™ protocol as the leading open global standard for secure, carrier-grade IoT LPWA connectivity. With the technical flexibility to address the multiple IoT applications, both static and mobile, and a certification program to guarantee interoperability, LoRaWAN™ has already being deployed by major mobile network operators globally and is anticipated to widely expand in 2016. www.lora-alliance.org
Mr. Markus Ridder
+49 2842 981-384
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00 | Pressemelding
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01 | Pressemelding
GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom